A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Pimavanserin (Primary)
- Indications Aggression; Agitation
- Focus Therapeutic Use
- Sponsors Acadia Pharmaceuticals
- 05 Dec 2017 Planned number of patients changed from 432 to 120.
- 05 Dec 2017 Planned End Date changed from 1 Jul 2019 to 1 Feb 2018.
- 05 Dec 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Feb 2018.